Detalles de la búsqueda
1.
Randomized Phase II trial of nintedanib, afatinib and sequential combination in castration-resistant prostate cancer.
Future Oncol
; 10(2): 219-31, 2014 Feb.
Artículo
en Inglés
| MEDLINE | ID: mdl-24490608
2.
Improved survival in a cohort of trial participants with metastatic castration-resistant prostate cancer demonstrates the need for updated prognostic nomograms.
Eur Urol
; 64(2): 300-6, 2013 Aug.
Artículo
en Inglés
| MEDLINE | ID: mdl-23313031
3.
Clinical and biochemical consequences of CYP17A1 inhibition with abiraterone given with and without exogenous glucocorticoids in castrate men with advanced prostate cancer.
J Clin Endocrinol Metab
; 97(2): 507-16, 2012 Feb.
Artículo
en Inglés
| MEDLINE | ID: mdl-22170708
4.
Selective inhibition of CYP17 with abiraterone acetate is highly active in the treatment of castration-resistant prostate cancer.
J Clin Oncol
; 27(23): 3742-8, 2009 Aug 10.
Artículo
en Inglés
| MEDLINE | ID: mdl-19470933
5.
Characterization of ERG, AR and PTEN gene status in circulating tumor cells from patients with castration-resistant prostate cancer.
Cancer Res
; 69(7): 2912-8, 2009 Apr 01.
Artículo
en Inglés
| MEDLINE | ID: mdl-19339269
Resultados
1 -
5
de 5
1
Próxima >
>>